Steatohepatitis/Metabolic Liver Disease News

Non-heavy alcohol consumption was associated with fibrosis and at-risk nonalcoholic steatohepatitis, prompting researchers to suggest that current fatty liver disease categorization as alcoholic or nonalcoholic may be “misleading.”

Blood endotoxin levels were increased among patients with nonalcoholic fatty liver disease compared with healthy controls and may serve as a relevant diagnostic biomarker, according to research in Clinical Gastroenterology and Hepatology.

Topline findings from the phase 3 MAESTRO-NASH trial showed that resmetirom at both 100 mg and 80 mg doses improved resolution of nonalcoholic steatohepatitis without worsening fibrosis, Madrigal Pharmaceuticals announced.

Results from a meta-analysis underscored the need to improve understanding of nonalcoholic fatty liver disease burden and management in at-risk individuals who are overweight and obese.

WASHINGTON — The term ‘non-alcoholic fatty liver disease’ no longer reflects current knowledge of the disease and should be changed, members of the NAFLD Nomenclature steering committee noted during The Liver Meeting.

The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.

CVD risk increases with the severity of nonalcoholic fatty liver disease, and both CV and liver events are “highly related” to the degree of hepatic fibrosis present, according to a speaker.

CHARLOTTE, N.C. — Elevated ferritin correlated with an increased prevalence of cirrhosis — but not congestive heart failure — in patients with metabolic dysfunction-associated fatty liver disease, according to a presenter here.

CHARLOTTE, N.C. —Nonalcoholic fatty liver disease prevalence rose more than 50% globally from 1990 to 2019, with African and Middle Eastern regions identified as hotspots, according to data presented at ACG Annual Scientific Meeting.

WASHINGTON — Bulevirtide monotherapy was safe and effective at 72 weeks for patients with hepatitis D virus-related compensated cirrhosis, with virological and clinical responses increasing over time, according to data presented here.